The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|94|4|343-354

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.94, Iss.4, 2015-04, pp. : 343-354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy

By                

International Journal of Molecular Medicine, Vol. 31, Iss. 6, 2013-01 ,pp. : 1449-1456

Spandidos Publications

Access to resources Recommend Favorite

Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1747-1759

John Wiley & Sons Inc

Access to resources Recommend Favorite

Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1747-1759

John Wiley & Sons Inc

Access to resources Recommend Favorite

Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer

By  

HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Vol. 37, Iss. 5, 2015-05 ,pp. : 636-643

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell malignancies

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 175, Iss. 1, 2016-10 ,pp. : 55-65

John Wiley & Sons Inc

Access to resources Recommend Favorite